Manejo diagnóstico y actitud terapeútica de 1156 pacientes diagnosticados de cáncer de próstata en la comunidad de Castilla y León durante el año 2014

Virseda-Rodríguez, Álvaro Julio; Marcos Asensio, Sara; Núñez-Otero, Juan Jesús; García, Fructuoso; Sanz, Alejandro; Gutiérrez, Emilio; Serrano, José María; Valverde, Sebastián; Polo, Carlos; Heriberto Amón-Sesmero, José; Rodríguez, Verónica; Cortiñas, Ramón; Calleja, Jesús; Adriazola, Miguel; Gala, Lucía; Bermúdez, Raul; Moya, Ignacio; Szczesniewski, Ryszard; López-Aramburu, Miguel Ángel; Gómez-Veiga, Francisco.
Arch. esp. urol. (Ed. impr.) ; 72(5): 463-470, jun. 2019. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-188984

Documentos relacionados

  1. [Diagnostic and therapeutic management in a series of 1156 patients with the diagnosis of prostate cancer in Castilla y Leon during 2014.]
  2. [Omics molecular subtyping, prognostic prediction and individualized treatment of prostate cancer: Advances in studies].
  3. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
  4. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
  5. Large cribriform glands (> 0.25 mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer.
  6. New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.
  7. Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome.
  8. Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer.
  9. Multiparametric MRI-based 5-year Risk Prediction Model for Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy.
  10. Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data.